| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Akebia Therapeutics, Inc. (AKBA) has 10 insiders with recent SEC Form 4 filings, including 1 buy and 5 sells. AKBA is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 3.46M | $4.02M | - | |
| CFO | 320.0K | $371.2K | - | |
| Dir | 160.9K | $186.7K | - | |
| Dir | 129.5K | $150.2K | - | |
| VP | 119.0K | $138.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 2, 2015 | Nash Duane | Director | Sell | 996 | $9.53 | $9,489.89 | -3.0% | |
| Apr 22, 2015 | Satter Muneer A58 | Director | Buy | 420,000 | $8.25 | $3,465,000.00 | +26.5% | |
| Apr 2, 2015 | Nash Duane | Director | Sell | 996 | $9.09 | $9,051.75 | -7.7% | |
| Apr 2, 2015 | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,483 | $9.09 | $13,477.65 | -1.9% | |
| Jan 2, 2015 | Hadas Nicole R.60 | VP General Counsel &Secretary | Sell | 1,715 | $11.46 | $19,655.10 | -2.3% | |
| Jan 2, 2015 | Nash Duane | Director | Sell | 995 | $11.46 | $11,403.40 | -7.2% |